Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–116 of 116 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Inhaler Device Clear all

Conditions: Asthma
Interventions: Propeller Health System (formerly Asthmapolis System); Device
Lead sponsor: Reciprocal Labs; Industry
Eligibility: 5 Years to 90 Years
Enrollment: 495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Woodland, California

Conditions: Human Immunodeficiency Virus, Smoking
Interventions: Bupropion, Varenicline, Cognitive Behavioral Therapy, Nicotine Replacement Therapy, Relapse Prevention Text Messaging; Drug · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Asthma in Children
Interventions: Digihaler Albuterol Device by TEVA; Device
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 8 Years to 18 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions: AZD7594 Solution for infusion (150 μg intravenous formulation), AZD7594 Oral suspension (1200 μg oral formulation), AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler), AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler), AZD7594 Pressurized inhalation suspension (400 μg) by pMDI; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatic Impairment
Interventions: Treprostinil Palmitil Inhalation Powder; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Lake Forest, California • San Dimas, California • Orlando, Florida + 1 more

Conditions: Asthma
Interventions: Fluticasone propionate/salmeterol, Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder, Placebo; Drug
Lead sponsor: West-Ward Pharmaceutical; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 1,556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Olodaterol/Tiotropium Bromide, Umeclidinium/ Vilanterol; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 1 Year to 40 Years
Enrollment: 11,296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: In-Check Dial, Inhaler Device; Device
Lead sponsor: Winthrop University Hospital; Other
Eligibility: 4 Years to 8 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Asthma
Interventions: Albuterol Sulfate; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 44
States / cities: Litchfield Park, Arizona • Bakersfield, California • Los Angeles, California + 37 more

Conditions: Asthma
Interventions: Inhaled corticosteroids, eNO measurement; Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 20 Years
Enrollment: 547 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 12
States / cities: Tucson, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 9 more

Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 19
States / cities: Phoenix, Arizona • Fresno, California • Los Angeles, California + 15 more

Conditions: Persistent Asthma
Interventions: Beclomethasone Dipropionate 640, Placebo, Beclomethasone dipropionate via 320 mcg BAI, albuterol/salbutamol, Beclomethasone dipropionate via 320 mcg MDI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 713 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 75
States / cities: Peoria, Arizona • Downey, California • Huntington Beach, California + 59 more

Conditions: Asthma
Interventions: Fluticasone Furoate/ Vilanterol 200/25 mcg, Fluticasone Furoate/ Vilanterol 100/25 mcg, Fluticasone Furoate 100 mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 1,040 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 37
States / cities: Little Rock, Arkansas • Huntington Beach, California • Los Angeles, California + 33 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Glycopyrronium bromide, Placebo to glycopyrronium bromide, Tiotropium; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 1,066 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 75
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol 300 μg, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Torrance, California • Lebanon, New Hampshire

Conditions: Asthma, Copd, Acute Exacerbation of COPD
Interventions: Inhaler Trainer System, Initial Inhaler Use Assessment, Inhaler Use Instruction; Device · Other
Lead sponsor: Koronis Biomedical Technologies; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Danirixin 35 mg tablets, Placebo, Metered dose inhaler (MDI) sensor device, Rescue medication; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 76 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 11
States / cities: Birmingham, Alabama • San Diego, California • Torrance, California + 8 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 1,626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 94
States / cities: Birmingham, Alabama • Jasper, Alabama • Peoria, Arizona + 85 more

Conditions: Myocardial Infarction
Interventions: CalmioGO Stress management device; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Asthma
Interventions: Meducation device technique video, Nutrition video; Behavioral · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 8 Years to 16 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Thomasville, North Carolina

Search by objective public record fields.

Effectiveness of the Propeller Health (Formerly Asthmapolis) Monitoring System

Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH)

Albuterol Integrated Adherence Monitoring in Children With Asthma

A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects

A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)

A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Evaluation of Negative Inspiratory Flow in Children With Acute Asthma

A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Asthma

Evaluation of an Asthma Treatment Strategy Based on Exhaled Nitric Oxide Measurements in Adolescents

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)

The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Inhaler Trainer Efficacy Study

A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)

A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Examination of the Impact of CalmiGo's Stress Management Device on Vascular Heath and Cardiovascular Disease Risk.

ENLaCE Pilot Study